Source: Virtual Congress 2020 – Rethinking asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Idzko (Wien, Austria). What is it about responders and non-responders in asthma? From biology to physiology and treatment. Virtual Congress 2020 – Rethinking asthma

Member's Comments

No comment yet.

Related content which might interest you: Who should receive which biologic and why? Current and future approaches in severe asthma patients Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what? Year: 2021 What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance Source: ERJ Open Res, 7 (1) 00497-2020; 10.1183/23120541.00497-2020 Year: 2021 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Linking phenotypes to personalised treatments in asthma and COPD Source: Virtual Congress 2021 – Precision medicine in asthma and COPD Year: 2021 When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma? Source: Eur Respir J, 58 (3) 2100304; 10.1183/13993003.00304-2021 Year: 2021 Application of biomarkers and patient characteristics to personalize asthma treatment for children Source: International Congress 2016 – Deep phenotyping to improve treatment outcomes in paediatric asthma Year: 2016 What is the role of genetics in occupational asthma? Source: Eur Respir J 2009; 33: 459-460 Year: 2009 The pharmacogenetic aspects of corticosteroid metabolism in patients with severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 523s Year: 2006 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 What can we learn from models to study exacerbation mechanisms in asthma and COPD? Source: Annual Congress 2010 - Severe exacerbations in asthma and COPD: new causes, mechanisms and models of care Year: 2010 Are a degree of asthma therapy related to asthma control impairment? Source: Eur Respir J 2003; 22: Suppl. 45, 370s Year: 2003 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 What is the role of oral corticosteroids in the era of biologics in asthma? Source: International Congress 2019 – State of the art session: Airway disease Year: 2019 Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis? Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy Year: 2017 Introduction: pharmacogenetic approaches in the treatment of asthma Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology Year: 2005 The role of the individual rehabilitation programs in the complex treatment of the patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 519s Year: 2004 The biology of COPD Source: International Congress 2019 – An update on chronic obstructive pulmonary disease Year: 2019 What defines a COPD patient as a responder to rehabilitation? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 COPD exacerbations and adherence to treatment improvement:what goal can be achieved? Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020